EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

TheStreet Wire

Human Genome Sciences Inc (HGSI): Today's Featured Health Care Loser

By TheStreet Wire 06/05/12 - 05:01 PM EDT

Find out if (HGSI) is in Cramer's Portfolio.

Human Genome (HGSI) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 0.9%. By the end of trading, Human Genome fell 8 cents (-0.6%) to $13.38 on light volume. Throughout the day, 2.8 million shares of Human Genome exchanged hands as compared to its average daily volume of 7.6 million shares. The stock ranged in price between $13.35-$13.60 after having opened the day at $13.38 as compared to the previous trading day's close of $13.46. Other company's within the Health Care sector that declined today were: Aoxing Pharmaceutical Company (AXN), down 13.1%, Cleveland BioLabs (CBLI), down 13%, Graymark Healthcare (GRMH), down 12.6%, and Achillion Pharmaceuticals (ACHN), down 9.6%.

Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. Its principal products include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Human Genome has a market cap of $2.7 billion and is part of the drugs industry. Shares are up 82.1% year to date as of the close of trading on Monday. Currently there are seven analysts that rate Human Genome a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Human Genome as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally weak debt management.

You can view the full Human Genome Ratings Report.

On the positive front, Amyris (AMRS), up 27.5%, Marshall Edwards (MSHL), up 19.6%, American Caresource Holdings (ANCI), up 15.6%, and Tengion (TNGN), up 13.8%, were all gainers within the health care sector with Aetna (AET) being today's featured health care sector winner.

Use our health care section to find sector-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

Find other investment ideas from our top rated ETFs lists.

For more information on Human Genome Sciences Inc click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Real Money

TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:

Jim Cramer + 20 Wall Street pros
Intraday commentary & news
Real-time trading forum
Actionable trade ideas

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.